In the Real World Study, the Efficacy and Adverse Reactions of Ticagrelor on Ischemic Cerebrovascular Disease

Stroke Clinical Trial

Official title:

Real-world Study on the Efficacy and Safety of Ticagrelor in the Treatment of Ischemic Cerebrovascular Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05716646
• Other study ID #: QFS-HX-2022-TGRL-001
• Status: Not yet recruiting
• Start date: April 2023
• Est. completion date: December 2028

Study information

• Verified date: January 2023
• Source: Qianfoshan Hospital
• Contact: Huang Xin
• Phone: 13791120711
• Email: 13791120711[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a forward-looking, open, one-arm, and real clinical trial world. The researchers plan to recruit at least 50 qualified patients. The main purpose of this study is to establish a population pharmacokinetic model of ticagrelor , explore the correlation between its blood concentration and the events of ischemia and the adverse effects of hemorrhage, and evaluate the effectiveness and safety of ticagrelor in the treatment of ischemic cerebrovascular disease.

Description:

Ischemic stroke and transient ischemic attack are the most common types of ischemic cerebrovascular disease. Patients will suffer from physiological function damage, even mental symptoms, social function and other obstacles, seriously affecting the quality of life, and bringing heavy burden to families and society. Ticagelor is a new P2Y12 receptor antagonist. Compared with clopidogrel, ticagelor has stronger and more lasting platelet inhibition, and can reduce the recurrence of ischemic events in patients with acute coronary syndrome . Therefore, at least 50 patients with ischemic cerebrovascular disease using ticagelor will be included. Before and after treatment, the laboratory examination data, NIHSS, mRS, combined medication and adverse events, and ischemic events of the patients will be collected. The population pharmacokinetics model of Ticagelor was established to evaluate its effectiveness and safety.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: December 2028
• Est. primary completion date: December 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Female or male aged = 18 years.

2. Clinically diagnosed as ischemic cerebrovascular disease.

3. Take ticagelor for antiplatelet therapy.

4. Provision of informed consent.

Exclusion Criteria:

1. Head CT or MRI suggests the presence of intracranial hemorrhagic disease.

2. People with tumors and other serious systemic diseases.

3. Allergy to ticagelor.

Related Conditions & MeSH terms

• Cerebral Infarction
• Cerebrovascular Disorders
• Infarction
• Ischemia
• Ischemic Cerebrovascular Disease
• Nervous System Diseases
• Stroke

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Qianfoshan Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation between blood drug concentration and adverse events	Try to find the relationship between pharmacokinetic parameters and adverse events	6 months
Secondary	The incidence of adverse events caused by treatment	In a clinical trial, the probability of an unexpected and adverse medical event that occurs after a patient or clinical subject receives a trial drug, but it does not necessarily have a causal relationship with the treatment.	6 months
Secondary	NIHSS	NIH stroke scale (NIHSS) to assess the degree of neurological deficit in stroke patients. The score ranges from 0 to 42 points, the higher the score, the more severe the nerve damage. Patients with a baseline assessment of> 16 points are likely to die, while those with a score of <6 are likely to recover well; for each additional point, the probability of a good prognosis is reduced by 17%	6 months
Secondary	mRS	Modified Rankin scale (mRS) is an indicator of the efficacy of functional disability. The score ranges from 0 to 5 points, and the clinical score will be increased to 6 points to indicate death. The higher the score, the more disability the patient is.	6 months